- Home
- VMD vs TLSI Comparison
VMD vs TLSI Comparison
Compare VMD & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- TLSI
- Stock Information
- Founded
- VMD 2006
- TLSI 2010
- Country
- VMD United States
- TLSI United States
- Employees
- VMD N/A
- TLSI N/A
- Industry
- VMD
- TLSI Medical Specialities
- Sector
- VMD
- TLSI Health Care
- Exchange
- VMD Nasdaq
- TLSI Nasdaq
- Market Cap
- VMD 280.4M
- TLSI 244.3M
- IPO Year
- VMD N/A
- TLSI N/A
- Fundamental
- Price
- VMD $6.87
- TLSI $4.73
- Analyst Decision
- VMD
- TLSI Strong Buy
- Analyst Count
- VMD 0
- TLSI 4
- Target Price
- VMD N/A
- TLSI $11.13
- AVG Volume (30 Days)
- VMD 177.7K
- TLSI 118.6K
- Earning Date
- VMD 11-05-2025
- TLSI 11-13-2025
- Dividend Yield
- VMD N/A
- TLSI N/A
- EPS Growth
- VMD 47.14
- TLSI N/A
- EPS
- VMD 0.34
- TLSI N/A
- Revenue
- VMD $240,884,000.00
- TLSI $35,990,000.00
- Revenue This Year
- VMD $19.22
- TLSI $56.79
- Revenue Next Year
- VMD $17.51
- TLSI $54.15
- P/E Ratio
- VMD $20.41
- TLSI N/A
- Revenue Growth
- VMD 17.11
- TLSI 45.50
- 52 Week Low
- VMD $5.93
- TLSI $3.42
- 52 Week High
- VMD $9.81
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- VMD 51.33
- TLSI 48.36
- Support Level
- VMD $6.71
- TLSI $4.42
- Resistance Level
- VMD $7.04
- TLSI $4.67
- Average True Range (ATR)
- VMD 0.20
- TLSI 0.23
- MACD
- VMD 0.01
- TLSI -0.03
- Stochastic Oscillator
- VMD 67.92
- TLSI 61.87
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.